Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

Crohn's disease, a type of chronic inflammatory bowel disease (IBD), often causes scar-like tissue to build up in the ...

The biopharmaceutical firm has received market approval for the biosimilar in major markets such as Korea, Europe and Canada, with the United States being the latest addition.   The global market ...

Treating Newly-Diagnosed Crohn's Patients With Advanced Therapy Leads to Dramatic Improvements in Outcomes Feb. 22, 2024 — A large-scale clinical trial of treatment strategies for Crohn's ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...

This week marks the annual Crohn’s and Colitis Awareness Week, which recognizes two conditions that are related to ...

The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group. A group of patients with ...

Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...

The drug has received a nod from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Crohn's disease, a type of chronic inflammatory bowel disease (IBD), often causes scar-like tissue to build up in the ...